Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer

E-ISSN： 1875-5992|8|5|481-487

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.8, Iss.5, 2008-06, pp. : 481-487

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells

International Journal of Oncology, Vol. 46, Iss. 3, 2015-01 ,pp. : 1405-1411

Spandidos Publications

Access to resources Recommend Favorite

Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer

Oncology Reports, Vol. 28, Iss. 6, 2012-01 ,pp. : 2211-2216

Spandidos Publications

Access to resources Recommend Favorite

Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 303-308

Spandidos Publications

Access to resources Recommend Favorite

Receptor tyrosine kinases and the regulation of hematopoiesis

By Paulson R.F. Bernstein A.

Seminars in Immunology, Vol. 7, Iss. 4, 1995-04 ,pp. : 267-277

Academic Press

Access to resources Recommend Favorite

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

By Carlson Robert

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1049-1056

Springer Publishing Company

Access to resources Recommend Favorite